Collaboration Announcement

RNS Number : 1781C
Advanced Oncotherapy PLC
11 April 2013
 



ADVANCED ONCOTHERAPY PLC

 

("Advanced Oncotherapy" or "the Company")

 

COLLABORATION ANNOUNCEMENT

 

Advanced Oncotherapy (AVO) is pleased to announce a newly established synergy collaboration between CERN and Application of Detectors and Accelerators to Medicine SA ("ADAM") .

 

A team of experts in accelerator and detector technology from CERN founded ADAM with Italian entrepreneur Dr Alberto Colussi in 2007. ADAM aims to capitalise on the know-how and infrastructure that CERN provides to build innovative accelerators for proton therapy and for conventional radiotherapy.

 

ADAM's research and development activities have focused on two main fields: the design and construction of compact linear accelerators for conventional radiotherapy, and of compact linear accelerators for proton therapy. The next phase of the collaboration, a newly established synergy between ADAM,CERN and AVO will complete the Proton Beam accelerator complex.

 

"For CERN the transfer of technology and know-how in the medical field is an important part of the impact of basic science on societal issues," says CERN Director of Accelerators and Technology Steve Myers. "This partnership is a pragmatic way to share our competences and know-how with industrial partners who are able to bring this innovative medical solution to the market."

 

 

For further information, please contact:

 

Michael Sinclair,

Chief Executive

Sandy Jamieson

Jon Levinson

Simon Hudson,

Advanced Oncotherapy Group Plc

Libertas Capital Corporate Finance Ltd

Peterhouse Corporate Finance

Tavistock Communications

0203 617 8739

(NOMAD & Joint Broker)

(Joint Broker)

(Financial PR & IR)


020 7569 9650

020 7469 0930

020 7920 3150

 

 

 

About Advanced Oncotherapy

 

Advanced Oncotherapy is a provider of new technology for innovative and patient-focused cancer treatments. These are technologies endorsed internationally by UK and global cancer clinicians, but not currently available in the NHS nor the private sector. Such initiatives build on the Group's 28.75% stake in Advanced Proton Solutions (Holdings) Ltd and its Oncotherapy Resources business focused on non-melanoma skin cancer and early stage breast cancer. Advanced Proton Solutions is pioneering the use of Proton Beam Therapy in the UK. They have secured planning approval for its first proton beam therapy center in the UK in the City of London. In 2011, over 70,000 patients were treated worldwide with proton beam therapy in 32 centres.

 

-ends-


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCBUGDSXSBBGXB
UK 100